Pacific Biosciences Of California (PACB) EBIAT (2016 - 2025)
Historic EBIAT for Pacific Biosciences Of California (PACB) over the last 17 years, with Q3 2025 value amounting to -$38.0 million.
- Pacific Biosciences Of California's EBIAT rose 3742.28% to -$38.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$503.6 million, marking a year-over-year decrease of 2774.81%. This contributed to the annual value of -$309.9 million for FY2024, which is 101.59% down from last year.
- As of Q3 2025, Pacific Biosciences Of California's EBIAT stood at -$38.0 million, which was up 3742.28% from -$41.9 million recorded in Q2 2025.
- Pacific Biosciences Of California's 5-year EBIAT high stood at $16.5 million for Q3 2021, and its period low was -$426.1 million during Q1 2025.
- Its 5-year average for EBIAT is -$85.2 million, with a median of -$71.4 million in 2022.
- Examining YoY changes over the last 5 years, Pacific Biosciences Of California's EBIAT showed a top increase of 16977.39% in 2021 and a maximum decrease of 702828.84% in 2021.
- Over the past 5 years, Pacific Biosciences Of California's EBIAT (Quarter) stood at -$69.3 million in 2021, then decreased by 21.72% to -$84.4 million in 2022, then grew by 2.8% to -$82.0 million in 2023, then soared by 102.89% to $2.4 million in 2024, then plummeted by 1702.7% to -$38.0 million in 2025.
- Its EBIAT stands at -$38.0 million for Q3 2025, versus -$41.9 million for Q2 2025 and -$426.1 million for Q1 2025.